Evidence map›Paper›PMID 28567500›Full record

ReviewCurrent treatment options in neurology2017

Treatment of Sleep Dysfunction in Parkinson's Disease.

Amy W Amara, Lana M Chahine, Aleksandar Videnovic

Open access · greenAbstract readReview
In one paragraph

Review in Current treatment options in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2020
    Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Effects of exercise on sleep spindles in Parkinson's disease.Frontiers in rehabilitation sciences · 2022
    Article
  17. Article
  18. Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022
    Review
  19. Management of Sleep Disturbances in Parkinson's Disease.Journal of Parkinson's disease · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Amy W AmaraDivision of Movement Disorders, Department of Neurology, University of Alabama at Birmingham, SC 360A, 1720 2nd Ave S, Birmingham, AL, 35294-0017, USA. amyamara@uab.edu.
Lana M ChahineParkinson's Disease and Movement Disorders Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Aleksandar VidenovicNeurobiological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital · USUniversity of Alabama at Birmingham · USUniversity of Pennsylvania · US

Funding

Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Bright light modulation of non-motor symptoms in Parkinson's diseaseR01NS099055 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI VIDENOVIC, ALEKSANDAR · 2017 to 2021
$3.0M
The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD PatientsK23NS080912 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMARA, AMY WILLIS · 2012 to 2016
$934k
NINDS NIH HHS K23 NS080912NINDS NIH HHS P50 NS053488NINDS NIH HHS R01 NS099055
6 · The paper itself

Abstract

opinion statementImpaired sleep and alertness affect the majority of Parkinson's disease (PD) patients, negatively impacting safety and quality of life. The etiology of impaired sleep-wake cycle in PD is multifactorial and encompasses medication side effects, nocturnal PD motor symptoms, and presence of co-existent sleep and neuropsychiatric disorders. The primary neurodegenerative process of PD involves brain regions that regulate the sleep-wake cycle, such as brainstem and hypothalamic nuclei. Sleep disorders in PD include insomnia, REM sleep behavior disorder (RBD), sleep disordered breathing (SDB), restless legs syndrome (RLS), and circadian disruption. Despite its high prevalence in the PD population, there is a paucity of clinical studies that have investigated treatment of sleep dysfunction associated with PD. Therefore, we aim to review available evidence and outline treatment strategies for improvement of disorders of sleep and wakefulness in PD patients. Evidence supporting the efficacy of pharmacological and non-pharmacological treatment strategies in PD is limited. There is thus a great need but also opportunity for development of well-designed clinical trials for impaired sleep and alertness in PD. Providing education about sleep hygiene and strategies for its implementation represents the initial step in management. Prompt diagnosis and treatment of co-existent primary sleep and psychiatric disorders are critical, as this may significantly improve sleep and alertness. While the optimal treatment for insomnia in PD has not been established, available strategies include cognitive-behavioral therapy, medications with soporific properties, and light therapy. Safety measures, clonazepam, and melatonin are the mainstay of treatment for RBD. Continuous positive airway pressure is an effective treatment for SDB in PD. The treatment algorithm for RLS associated with PD mirrors that used for idiopathic RLS. Circadian disruption has emerged as an important etiology of impaired sleep-wake cycles in PD, and circadian-based interventions hold promise for novel treatment approaches.

Indexed as

Circadian rhythm disorderExcessive daytime sleepinessNon-motor symptomsParkinson’s diseaseREM sleep behavior disorderSleep

Identifiers

PMID28567500
PMCPMC6371969
OpenAlexW2618487552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.